A cellular viability screen using an FDA-approved drug library (Supplementary Data 2) was conducted on MIA PaCa-2, a pancreatic cancer cell line moderately sensitive to OFD1 knockdown (Fig. 2b). The gene discussed is OFD1; the disease is pancreatic neoplasm.